Description:
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous
PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is
relapsing during treatment with ibrutinib or acalabrutinib.
Title
- Brief Title: Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL
- Official Title: A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical Trial IDs
- ORG STUDY ID:
IOV-CLL-01
- NCT ID:
NCT04155710
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
Drug | Synonyms | Arms |
---|
IOV-2001 | Autologous PBL | Cohort 1a |
Low dose IL-2 | Interleukin-2 | Cohort 1a |
High dose IL-2 | Interleukin-2 | Cohort 1b |
IL-2 | Interleukin-2 | Cohort 2 |
Purpose
This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous
PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is
relapsing during treatment with ibrutinib or acalabrutinib.
Detailed Description
This study involves patients receiving nonmyeloablative (NMA) lymphocyte depleting (LD)
preparative regimen prior to infusion of IOV-2001 followed by IL-2 administration.
In Phase 1, patients meeting the eligibility criteria will be enrolled and will receive
treatment with IOV-2001 followed by low dose IL-2 or high dose IL-2.
After completion of Phase 1, the recommended Phase 2 dose (RP2D) will be evaluated in
selected patient cohorts defined in the Phase 2 part of the study.
Trial Arms
Name | Type | Description | Interventions |
---|
Cohort 1a | Experimental | CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + low dose IL-2. | |
Cohort 1b | Experimental | CLL/SLL patients whose disease has relapsed or is relapsing post ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + high dose IL-2. | |
Cohort 2 | Experimental | CLL/SLL patients with del 17p who progressed or are progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2. | |
Cohort 3 | Experimental | CLL/SLL patients without del 17p who progressed or progressing on ibrutinib or acalabrutinib therapy. Patients will receive IOV-2001 + IL-2. | |
Eligibility Criteria
Inclusion Criteria:
1. Patients with CLL or SLL with radiographically measurable disease
- Cohort 2 only: patients with progressed or progressing CLL/SLL on ibrutinib or
acalabrutinib with del 17p and/or TP53 mutated
- Cohort 3 only: patients with progressed or progressing CLL/SLL on ibrutinib or
acalabrutinib without del 17p and/or TP53 mutated
2. Patients must have documented progression or be progressing on ibrutinib or
acalabrutinib, as indicated by the presence of known BTK resistance mutation
3. Patients must have received at least 1 prior regimen (only for patients without del
17p and/or TP53 mutated) and currently be on ibrutinib or acalabrutinib. For patients
on combination therapy as the last line of therapy prior study entry, progression to
any of the individual components of the combination therapy, rather than to the
combination regimen, is required.
- For Cohort 2: The single prior regimen can be ibrutinib or acalabrutinib (ie,
patients are eligible while progressing on their first line of therapy)
- For Cohort 3: Patients must have progressed on at least 1 additional line of
therapy in addition to ibrutinib or acalabrutinib
4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 or 1 and an estimated life expectancy of ≥ 3 months.
5. Patients must have adequate bone marrow function to receive NMA-LD
6. Pulmonary function assessed by spirometry demonstrating FEV1 > 50% predicted normal
7. Cardiac function demonstrating left ventricular ejection fraction (LVEF) > 45%
8. Patients of childbearing potential or their partners of childbearing potential must be
willing to practice an approved method of birth control during treatment and for 12
months after receiving the last protocol-related therapy.
Exclusion Criteria:
1. Patients who have received an organ allograft or prior cell transfer therapy within 20
years.
2. Patients with known or suspected transformed disease (ie, Richter's Transformation).
3. Patients who received treatment with any systemic chemotherapy, immunotherapy,
targeted small molecule inhibitors, or other biologic agents within 30 days or 5
half-lives, whichever is shorter, of IOV-2001 infusion with the exception of ibrutinib
or acalabrutinib
4. Patients with known involvement of central nervous system (CNS) by lymphoma or
leukemia
5. Patients who are on chronic systemic steroid therapy >5 mg/day prednisone equivalent
for any reason
6. Patients who have active systemic infections requiring systemic ABX, autoimmune anemia
or thrombocytopenia, coagulation disorders, or other active major medical illnesses of
the cardiovascular, respiratory, or immune system.
7. Patients who are seropositive for any of the following:
- Human immunodeficiency virus (HIV)-1 or HIV-2 antibodies
- Hepatitis B antigen (HbsAg) or anti-hepatitis B core total antibodies
(anti-HbcAb), or hepatitis C antibody (HCVAb)
8. Patients with active and chronic fungal, bacterial, or viral infection requiring IV
treatment
9. Patients who require treatment for anti-coagulation with a vitamin K antagonist
(warfarin)
10. Patients who have received a live or attenuated vaccine within 28 days of beginning
the preparative NMA-LD regimen
11. Patients who are pregnant or breastfeeding
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Phase I: RP2D (Recommended Phase 2 Dose) |
Time Frame: | up to one year or depending on when the recommended phase 2 dose is determined |
Safety Issue: | |
Description: | to determine the recommended Phase 2 dose of IOV-2001 followed by interleukin-2 (IL-2) |
Secondary Outcome Measures
Measure: | Phase 1: Adverse Events |
Time Frame: | up to one year or depending on when the recommended phase 2 dose is determined |
Safety Issue: | |
Description: | Incidence of adverse events (AEs) and serious AEs |
Measure: | Phase 1: Disease Assessment |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess the evidence of activity of IOV-2001 followed by IL-2 as measured by ORR per Investigator assessment |
Measure: | Phase 1: Disease Assessment |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess CR/CRi rate per Investigator as defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria for IOV-2001 followed by IL-2 |
Measure: | Phase 1: Disease Assessment |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess minimum residual disease (MRD)-negative rate for IOV-2001 followed by IL-2 |
Measure: | Phase 2: Disease Assessment (Separately for each cohort) |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess progression free survival (PFS) of IOV-2001 therapy followed by IL-2 |
Measure: | Phase 2: Disease Assessment (Separately for each cohort) |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess overall survival (OS) of IOV-2001 therapy followed by IL-2 |
Measure: | Phase 2: Disease Assessment (Separately for each cohort) |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess duration of response (DOR) of IOV-2001 therapy followed by IL-2 |
Measure: | Phase 2: Disease Assessment (Separately for each cohort) |
Time Frame: | up to two years |
Safety Issue: | |
Description: | To assess disease control rate (DCR) of IOV-2001 therapy followed by IL-2 |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Iovance Biotherapeutics, Inc. |
Trial Keywords
- Autologous Peripheral Blood Lymphocytes
- PBL
- IOV-2001
- CLL
- IL-2
- Adoptive Cell Therapy
- SLL
Last Updated
July 30, 2021